Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

17.23 +2.31 (+15.48%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Liquidia Corporation Shares Are Moving Lower Monday
Liquidia announced that the Food and Drug Administration granted tentative approval of YUTREPIA. 
Via Benzinga
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. 
Via Investor's Business Daily
Expert Ratings For Liquidia
Via Benzinga
Expert Outlook: Liquidia Through The Eyes Of 5 Analysts
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Liquidia
Via Benzinga
LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Liquidia Corporation
Via GlobeNewswire
7 Analysts Have This To Say About Liquidia
Via Benzinga
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
From Liquidia Corporation
Via GlobeNewswire
LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q2 2024
LQDA stock results show that Liquidia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
From Liquidia Corporation
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
From Liquidia Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024
LQDA stock results show that Liquidia missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
From Liquidia Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.